News

Biotechs snap up EU money
Enlarge image

FundingBelgiumGermanyIrelandNetherlandsUK

Biotechs snap up EU money

16.04.2013 - Biotechs involved in the bio-economy initiatives of five European countries pool their expertise in an EU project termed BioBaseNWE.

The partners from Bio Base Europe international non-profit organisation (BE), Ghent Bio-Energy Valley (BE), Bio Base Europe Training Center (NL), REWIN/Biobased Innovations (NL), German Cluster Industrielle Biotechnologie, Galway-based Competence Centre for Biorefining and Bioenergy (IRL) and the British National Non-Food Crops Centre (UK) have secured €6.2m from the European Commission.

The overall goal of the Bio Base NWE project is to drive growth and education in the bio-based economy in north-western Europe. The project gets 50% of its €12m overall budget through the INTERREG IVB North West Europe Programme, the other 50% from Agentschap Ondernemen (BE), Biobased delta (NL), Provincie Noord-Brabant (NL), Provincie Zeeland (NL), National University of Ireland NUI Galway, Industrial Development Agency (IDA) Ireland, Enterprise Ireland, and the National Development Plan Ireland. “Bio-based products are a growing area of interest for SMEs working in the chemical industry, agro-industry, plastics, fuels, food, textile and pharma industry“ stressed project manager Lieve Hoflack. „However, many SME’s find it difficult to bridge the gap between newly developed research and the commercial market,” she added.

The network will advise SMEs on how to get financial support for projects at a pilot plant in Ghent. This flexible pilot plant will selectively invest in equipment for promising technologies to promote further growth. The partnership will also develop and deliver programmes and tools for training skilled professionals for bio-based industries.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/biotechs-snap-up-bio-economy-money.html

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%

FLOP

  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%

FLOP

  • BIOTEST (D)27.24 EUR-60.8%
  • BIOTECH PHARMACON (N)9.43 NOK-46.1%
  • TRANSGENE (F)2.80 EUR-23.9%

TOP

  • ADOCIA (F)88.74 EUR587.4%
  • DBV TECHNOLOGIES (F)81.03 EUR328.7%
  • FORMYCON (D)28.70 EUR315.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.70 SEK-71.6%
  • NEOVACS (F)1.01 EUR-69.5%

No liability assumed, Date: 03.08.2015